Kimia Biosciences Limited

KIMIABL

INE285U01025

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:01:01 2024-06-21 am EDT			5-day change	1st Jan Change
52.04 ^INR	-0.84%		-7.32%	+41.41%

Jun. 14	Kimia Biosciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI
Jun. 14	Kimia Biosciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI

Kimia Biosciences Limited Announces Resignation of Abhishek Kumar Pandey from Company Secretary and Compliance Officer

September 30, 2021 at 08:08 am EDT

Kimia Biosciences Limited informed that Mr. Abhishek Kumar Pandey, has resigned from the post of Company Secretary and Compliance Officer (KMP) of the Company with effective from close of working hours of 26 November 2021. Company is in process to appoint another Company Secretary & Compliance officer for complying with the provisions of Section 203 of the Companies Act 2013.

Latest news about Kimia Biosciences Limited

Kimia Biosciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	Jun. 14	CI
Kimia Biosciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024	Jun. 14	CI
Kimia Biosciences Limited Announces Resignation of Mita Namonath Jha as Non- Executive, Non- Independent Director	Apr. 01	CI
Kimia Biosciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 14	CI
Kimia Biosciences Limited Appoints Mita Namonath Jha as an Non Executive, Non Independent Director of the Company	23-10-03	CI
Kimia Biosciences Names CFO	23-09-07	MT
Kimia Biosciences Limited Announces Chief Financial Officer Changes	23-09-07	CI
Kimia Biosciences Limited Announces Appointment of Ms. Mita Namonath Jha as an Additional Director (Non-Executive and Non-Independent Director )	23-08-28	CI
Kimia Biosciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14	CI
Kimia Biosciences Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-06-01	CI
Kimia Biosciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-06-01	CI
Kimia Biosciences Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-06-01	CI
Kimia Biosciences Names New CFO	23-02-12	MT
Kimia Biosciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-14	CI
Arti Resigns as Chief Financial Officer of Kimia Biosciences Limited	22-08-12	CI
Kimia Biosciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-12	CI
Kimia Biosciences CEO Resigns	22-05-30	MT
Kimia Biosciences Limited Appoints Sameer Goel as Chief Executive Officer	22-05-30	CI
Kimia Biosciences Limited Announces Resignation of Suneel Kapoor as Chief Executive Officer	22-05-23	CI
Kimia Biosciences Gets Nod to Manufacture Bemopedoic Acid Bulk drug.	22-05-17	MT
Kimia Biosciences Limited Announces Granted Permission to Manufacture and Marketing of Bemopedoic Acid Bulk Drug Under New Drug and Clincial Trials	22-05-17	CI
Kimia Biosciences Limited Announces Appointment of Lakshay Prakash as Company Secretary	22-05-16	CI
Kimia Biosciences Names New CFO	22-04-29	MT
Kimia Biosciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-14	CI
Kimia Biosciences Gets Regulatory Nod to Supply Pharmaceutical Raw Material to Bangladesh	21-12-29	MT

Chart Kimia Biosciences Limited

Duration

Period

More charts

Company Profile

Kimia Biosciences Limited is an India-based company, which is engaged in the business of pharmaceutical products. The Company provides its products under various categories: Commercial Active Pharmaceutical Ingredients (APIs), Commercial KSMs, Intermediates & Reagents. The Company's Commercial-APIs products include acotiamide hydrochloride hydrate, azelnidipine, benfotiamine, benidipine hydrochloride, citicoline sodium, gliclazide, dapagliflozin propanediol monohydrate, levosulpiride, luliconazole, oxaceprol, prucalopride succinate, teneligliptin hydrobromide hydrate, vildagliptin, fimasartan trihydrate potassium, obeticholic acid and ursodeoxycholic acid. Its Commercial KSMs, Intermediates & Reagents products include Ethyl-2-Amino 1,3-Thiazole 4-Carboxylate, 2,4,5-Trimethoxy Benzoic Acid, Ethyl 2-(2,4,5-trimethoxybenzamido)-1,3-thiazole-4-carboxylate, Isopropyl 2-(3-Nitrobenzylidene) Acetoacetate, Choline phosphate chloride calcium, and more.

Sector

Pharmaceuticals

Calendar

2024-08-11 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
KIMIA BIOSCIENCES LIMITED	+41.41%	29.68M
ELI LILLY AND COMPANY	+51.82%	798B
NOVO NORDISK A/S	+41.51%	633B
JOHNSON & JOHNSON	-5.03%	356B
MERCK & CO., INC.	+19.13%	328B
ABBVIE INC.	+10.18%	304B
ASTRAZENECA PLC	+17.66%	244B
ROCHE HOLDING AG	+3.39%	227B
NOVARTIS AG	+10.75%	216B
AMGEN INC.	+7.54%	166B